Latest

COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end

Roche to pay Atea $350M for ex-U.S. rights to COVID-19 antiviral

FDA greenlights expansion of COVID-19 study to VCU Medical Center after positive data

CalciMedica's Auxora Shows Promise As COVID-19 Treatment, Patients Recovered Twice As Fast